European multicenter harmonization study shows anaplastic lymphoma kinase immunohistochemistry testing comparable to, if not better than, fluorescence in situ hybridization testing.
DENVER – Sixteen institutions across Europe collaborated together to show for the first time that a semi-quantitative anaplastic lymphoma kinase (ALK) protein expression test, immunohistochemistry (IHC), is reliable amongst several laboratories and review
The American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines Committee (CPGC) identified a guideline for endorsement that addressed molecular testing for the selection of patients with lung cancer for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors. The target guideline was developed in 2013 as a joint product of the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP).
IASLC Announces Advocacy Travel Awards: International lung cancer patient advocates may apply to receive grants for WCLC 2015 in Denver
DENVER – The International Association for the Study of Lung Cancer (IASLC) has opened the application process for lung cancer patient advocates to apply for Advocacy Travel Awards. Awardees receive a travel stipend, free conference registration, up to four nights’ accommodation, and a complimentary IASLC Membership for 2016.
NCI/FDA lung cancer workshop leads to the innovatively designed clinical trials Lung-MAP and ALCHEMIST, the first “Master Protocol” trials
DENVER – The recent launch of two clinical trials offer innovative study designs for patients with lung cancer. These clinical trials are the direct result of a National Cancer Institute (NCI) sponsored workshop chaired by Drs. Fred R. Hirsch, Shakun Malik and Claudio Dansky- Ullman, that brought together the NCI Thoracic Malignancies Steering Committee, the US Food and Drug Administration (FDA), academicians, clinicians as well as industry and government stakeholders to discuss issues and challenges related to clinical trial design and biomarkers for lung cancer targeted-therapies.
DENVER – The average cost to screen high-risk individuals for developing lung cancer with low-dose computed tomography (LDCT) plus the average cost of curative intent treatment, like surgery, is lower than the average cost to treat advanced stage lung cancer, which quite rarely results in a cure.
Modest acute changes in cardiac biomarkers and electrocardiogram findings following thoracic radiation therapy.
DENVER – There were only modest acute changes in cardiac biomarkers and electrocardiograms and there were no clinically significant cardiac events in patients with high-dose radiation exposure to the heart following thoracic radiation therapy (RT) and short-term follow-up.